Long-term metabolic side effects of second-generation antipsychotics in Chinese patients with schizophrenia: A within-subject approach with modelling of dosage effects

This publication has 62 references indexed in Scilit:

• Metabolic side effects in persons with schizophrenia during mid‐ to long‐term treatment with antipsychotics: a network meta‐analysis of randomized controlled trials
  World Psychiatry, 2023
• Lipid Metabolism Disturbances During Antipsychotic Treatment for Schizophrenia
  2022
• Real-World Data on the Adverse Metabolic Effects of Second-Generation Antipsychotics and Their Potential Determinants in Adult Patients: A Systematic Review of Population-Based Studies
  Advances in Therapy, 2021
• Randomized Controlled Trials Versus Real World Evidence: Neither Magic Nor Myth
  Clinical Pharmacology & Therapeutics, 2020
• Obsessive–compulsive symptoms in psychotic disorders: longitudinal associations of symptom clusters on between- and within-subject levels
  European Archives of Psychiatry and Clinical Neuroscience, 2018
• Long-term metabolic effects of aripiprazole, ziprasidone and quetiapine: a pragmatic clinical trial in drug-naïve patients with a first-episode of non-affective psychosis
  Psychopharmacology, 2017
• Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta‐analysis
  World Psychiatry, 2015
• A family study of endophenotypes for psychosis within an early intervention programme in Hong Kong: Rationale and preliminary findings
  Chinese Science Bulletin, 2011
• Effectiveness of long-term aripiprazole therapy in patients with acutely relapsing or chronic, stable schizophrenia: a 52-week, open-label comparison with olanzapine
  Psychopharmacology, 2006
• A Meta-analysis of the Efficacy of Second-Generation Antipsychotics
  Archives of General Psychiatry, 2003